U.S. Supreme Court Temporarily Restores Access To Abortion Pill/Image@ BBC
The United States Supreme Court has ruled that the abortion pill Mifepristone can continue to be distributed by mail, a decision that comes amid ongoing legal challenges to its accessibility.
Two manufacturers of Mifepristone sought the Supreme Court’s intervention after a lower court imposed significant restrictions on the drug as part of a lawsuit.
The high court’s order, issued Thursday, temporarily blocks these limitations while the case is still pending. This means that access to the pill is likely to remain intact until a resolution is reached, which could take place next year.
Mifepristone is the most prevalent method for terminating pregnancies in the United States, particularly in regions where abortion services are prohibited. Notably, the Supreme Court’s most conservative justices, Clarence Thomas and Samuel Alito, dissented from the ruling.
In 2023, the Food and Drug Administration (FDA) permitted physicians to prescribe Mifepristone without requiring in-person consultations, enabling women to obtain the medication via mail or at pharmacies through telehealth services.
Last October, Louisiana filed a lawsuit against the FDA in an attempt to block the mail delivery of Mifepristone, arguing that nationwide distribution contravened the state’s abortion ban. Earlier this month, in response to this lawsuit, an appeals court reinstated a requirement mandating that abortion pills be acquired in person.
The appeals court stated, “Every abortion facilitated by FDA’s action nullifies Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is a human being from the moment of conception and is, therefore, a legal person.'”
Following this development, the manufacturers requested that the Supreme Court intervene while they prepared to file an emergency case.
The ruling issued Thursday, known as a stay, was part of the court’s emergency docket and did not include any reasoning. It will remain effective until the justices decide whether to hear the manufacturers’ appeal.
In his dissent, Thomas argued that since mailing Mifepristone is illegal in Louisiana, the manufacturers should not be entitled to block a court order based on “lost profits from their criminal enterprise.”
Mifepristone is the first medication in a two-drug regimen recommended by the FDA for terminating pregnancies and is widely accessible in states where abortion remains legal.
The availability of Mifepristone was expanded in April 2021 when the FDA lifted in-person dispensing requirements for the drug during the COVID-19 pandemic.
The following year, the U.S. Supreme Court overturned its long-standing Roe v. Wade decision, which had guaranteed women the constitutional right to an abortion, allowing individual states to impose bans on the procedure.
In 2023, the FDA made the decision to permanently allow Mifepristone to be sent by mail.
However, subsequent legal challenges have left room for further attempts to restrict access to the medication.
Since the overturning of Roe v. Wade, over 20 states have enacted bans or restrictions on abortion services.
By: Magdalene Agyeiwaa Sarpong